Pain

Introducing Protomentum – The Ideal Accelerated Product Development Partner

Retrieved on: 
Monday, April 8, 2024
Online, NOVA, HR, ASAP, Documentation, Headache, CNC, Electronics, FedEx, System, Pain, Risk management

SYDNEY, NOVA SCOTIA, April 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Protocase, the leader in B2B custom electronic enclosures and precision sheet metal fabrication for a wide range of industries including aerospace via its ProtoSpace division, is thrilled to announce the launch of its new division: Protomentum. This innovative venture is poised to revolutionize product development by providing an all-encompassing solution for founders, venture capitalists, innovators and established companies seeking rapid time-to-market via a single best-in-class partner with decades of proven processes and experience. Great products only happen after multiple iterations, and our ultra-fast manufacturing lets you iterate and refine quickly, achieving a much higher standard than possible with fewer, slower development cycles. Additionally, Protomentum's flexible manufacturing enables you to make multiple versions for market quickly for high-value, low-volume products.

Key Points: 
  • In today’s fast-paced business landscape where efficiency is do or die, time is of the essence, especially for early-stage companies and first-time product runs.
  • However, the traditional product development process often hinders progress due to fragmented workflows.
  • Current standalone options for product design are not ideal; the choice is either hiring an external design agency, or having mechanical designers/engineers on staff, both of which are cost prohibitive.
  • That’s why we created Protomentum, the one-stop solution for rapid product development and a true game changer in manufacturing solutions.

Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities

Retrieved on: 
Monday, April 8, 2024
Organization, Clobetasol, Disease, Inflammation, Near-sightedness, Sale, NDA, Mydriasis, Pain, FDA, Pharmaceutical industry

In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.

Key Points: 
  • In conjunction with the strategic process and focus on its late stage MicroPine asset, Eyenovia reiterated its immediate commercialization opportunities and corporate savings intended to reduce operating expenses while continuing to support meaningful value generation from the company's two FDA-approved products.
  • “The pediatric progressive myopia market represents a significant opportunity for Eyenovia both in the United States and China.
  • This disease, for which there are no FDA-approved pharmaceutical treatments, has been called an epidemic by several medical and optometric organizations.
  • Eyenovia does not intend to make any further disclosures regarding the strategic review process unless and until a specific course of action is approved.

Venus Concept Announces Israeli Regulatory Approval for Venus Bliss MAX

Retrieved on: 
Monday, April 8, 2024
Venus, Magnetic field, Communication, System, Spasm, Abdomen, History, Research, Human, Ministry of Health, Cellulite, Lipolysis, Annual report, Pain, Ministry, FDA

TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.

Key Points: 
  • TORONTO, April 08, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has received approval for the Venus Bliss MAX from the State of Israel Ministry of Health.
  • The Venus Bliss MAX was first launched commercially in the United States in Q1 2022 after FDA 510(k) clearance and offered internationally in approved jurisdictions.
  • The Venus Bliss MAX offers three advanced technologies in one platform: diode laser applicators, (MP)2 applicator that combines Multi-Polar Radio Frequency and Pulsed Electro Magnetic Fields with advanced VariPulse™ technology and the Company’s FlexMax EMS applicators.
  • “The Venus Bliss MAX has been well received internationally, and we look forward to bringing our comprehensive all-in-one platform to the Israeli aesthetic service providers,” said Dr. Hemanth Varghese, President and Chief Operating Officer of Venus Concept.

Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Inflammation, Pain, Patient, OCS

Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th.

Key Points: 
  • Dr. Donnenfeld presented the “Once Daily OCS-01, an OPTIREACH® Formulation of High Concentration Dexamethasone Eye Drop, for Inflammation and Pain Following Cataract Surgery – a Phase 3, Double-Masked, Vehicle-Controlled Study” on Sunday, April 7th.
  • The results showed that 57.2% of patients treated with OCS-01 were inflammation free (i.e.
  • absence of anterior chamber cells) at Day 15 (vs. 24.0% with vehicle, p
  • The two Phase 3 OPTIMIZE trials are expected to support an NDA submission.

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Nonprofit Supporting Retired Military Working Dogs Celebrates Milestone

Retrieved on: 
Thursday, April 4, 2024
Ankle, Dog, United States Army, Emergency, Pain, Nox, Pharmaceutical industry

BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- A non-profit with over 23 years’ service, supporting the military K-9 community, is celebrating the successful rollout of a new program which covers the cost of emergency treatments for retired military working dogs.

Key Points: 
  • BALTIMORE, April 04, 2024 (GLOBE NEWSWIRE) -- A non-profit with over 23 years’ service, supporting the military K-9 community, is celebrating the successful rollout of a new program which covers the cost of emergency treatments for retired military working dogs.
  • US War Dogs Association has already provided $50,000 of treatments to retired MWDs through its Emergency Care program, alleviating the financial burden from their handlers and families.
  • Retired US Army patrol and explosive detection dog (PEDD), Nox, is a recent beneficiary of US War Dogs’ Emergency Care program.
  • “We are only able to continue our vital work of supporting the military K-9 community, thanks to the generosity of our donors.

Ashley Expands Tempur-Pedic® Assortment with New TEMPUR-Adapt® Collection

Retrieved on: 
Thursday, April 4, 2024
Bedding, Pressure, Relaxation, Partnership, Time zone, Sleep, Tempur-Pedic, Movement, TEMPUR, Pain, Pet, Series, Collection

Combining one-of-a-kind TEMPUR-Material™ with new comfort innovations, the TEMPUR-Adapt collection is designed to deliver exceptional body-conforming pressure relief for full-body support and relaxation.

Key Points: 
  • Combining one-of-a-kind TEMPUR-Material™ with new comfort innovations, the TEMPUR-Adapt collection is designed to deliver exceptional body-conforming pressure relief for full-body support and relaxation.
  • The collection also features cool-to-the-touch covers and motion absorption to help minimize sleep disruptions caused by movements from partners, pets, or kids.
  • Every Tempur-Pedic purchase at Ashley helps to support Operation Shut-Eye, a program in partnership with Tempur-Sealy International and Darkhorse Benefits, a non-profit organization.
  • Ashley’s large assortment of mattress brand offerings include Sealy®, Stearns & Foster®, Ashley Sleep™, Purple®, and more.

Tilray Medical Announces New Scientific Publication on Age-Related Patterns of Medical Cannabis Use

Retrieved on: 
Wednesday, April 3, 2024
Epilepsy, CCPS, Health, TLRY, HIV, Arthritis, Post-traumatic stress disorder, Patient, Tilray, Anxiety, Tobacco, Chronic pain, CBD, Essential tremor, Cannabis, TSX, Signs and symptoms, Pain, THC, Vomiting, Pharmaceutical industry

NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada. The new study was derived from the Canadian Cannabis Patient Survey (CCPS) 2021, comprised of 2,697 patients and focused primarily on older patients with a mean age of 54.3. This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.

Key Points: 
  • Tilray Led Study Shows Chronic Pain, Arthritis, Anxiety, and Insomnia as Primary Illnesses and Symptoms for Medical Cannabis Use
    NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, today announced a new Tilray led scientific publication, Age-related Patterns of medical Cannabis Use: A Survey of Authorized Patients in Canada .
  • This study presents to the medical and scientific community the consumption trends observed in patients and the self-reported impacts from medical cannabis in alleviating the patients’ primary symptoms.
  • The Age-related Patterns of Medical Cannabis Use study finds that older patients comprise a growing subset of medical cannabis patients.
  • José Tempero, Tilray’s Medical Director, said, "Our role in this initiative exemplifies our commitment to medical research, leading us one step closer to unlocking the full therapeutic potential of medical cannabis."

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Retrieved on: 
Wednesday, April 3, 2024
Johns Hopkins Hospital, MLSS, Anesthesia, Risk, Trauma, MD, ESI, CPT, ASC, Injection, Safety, Spine, Pain management, Pain, Physician, Epidural steroid injection, Nursing

ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.

Key Points: 
  • ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida.
  • PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers.
  • PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.
  • Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida.

OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery

Retrieved on: 
Tuesday, April 2, 2024
NCP, Refractive surgery, ASCRS, Cataract, DED, Society, Pain, Telecanthus, FDA, Annual general meeting

LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.

Key Points: 
  • LONDON and NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated with pain but without an FDA approved therapy, today announced an upcoming presentation of the OK-101 Phase 2 data for dry eye disease at Eyecelerator 2024, a partner meeting of the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, being held April 4, 2024 in Boston, MA.